Bortezomib + Low Dose Cytarabine in Int-2 and High Risk MDS. Interim Results of a Phase I/II Trial by the GFM.

Shanti Natarajan,Pierre Fenaux,Norbert Vey,A. Guerci, I. Coulibaly,A. Charbonnier, C. Ravoet, S. Courby,G. Etienne, M.P. Chaury,S. Cheze,A. Stamatoullas,L. Legros, E. Berger, A. Lescoute, S. Vaultier,F. Dreyfus

Blood（2007）

引用 0|浏览0

暂无评分

摘要

Background: We (Blood . 2006; 107:1156) and others showed that marrow cells from high-risk MDS patients exhibit constitutive NF-kB activation. Bortezomib (BOR) is a specific inhibitor of NF-kB with limited efficacy when used alone in AML but which is potentiated by its association with chemotherapy especially Cytarabine (AraC) (Cancer Chem Pharm . 2006; 58:13).

查看译文

关键词

high risk mds,low dose,i/ii trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要